Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carvana Co (CVNA) vs Davita Inc (DVA) Price & Performance

Carvana CoTrade
Davita IncTrade

Price performance (Past 24H)

Key statistics

Carvana Co vs Davita Inc — how do they compare? Carvana Co trades at $70.5 (market cap $50.41B), while Davita Inc trades at $231.15 (market cap $14.92B). The key difference: Carvana Co is far larger — about 3.4× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.

CVNADVA
Market Cap
$50.41B$14.92B
Sector
Consumer CyclicalHealth
52-Week High
$95.69$235.71
52-Week Low
$56.27$103.87
Enterprise Value
$53.06B$27.47B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carvana Co

Carvana (CVNA) trades at $65.02, down 1.23% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32 billion in 2025 and a net income of $1.41 billion, though it missed Q3 2025 EPS estimates. Recent corporate actions include stock splits, and cash flow from operations remains positive at $1.04 billion in 2025. Analyst consensus is a Buy with a $93.62 price target, indicating significant upside potential from current levels.

The outlook for CVNA is mixed; robust revenue growth and improving profitability support bullish sentiment, but high valuation ratios (P/E of 37.65) and technical bearishness pose risks. Investors should weigh the company's scaling efficiency and market share gains against debt levels and competitive pressures in the e-commerce auto sector. The stock's proximity to support at $64 suggests near-term volatility, but analyst targets imply confidence in long-term value.

Davita Inc

DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.

The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Carvana Co

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.

Read more on CVNA

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA